Veru Inc.

VERU · Nasdaq · United States

Share price · VERU

$2.31-0.28 (-10.81%) 3M

close as of 2026-11-18 · 24h delayed · vol 467K (3.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VERU's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+7.9%
  2. 15 Oct 2026+14.6%
  3. 4 Jun 2026+88.0%
  4. 3 Jun 2026-4.3%

    Nothing announced by VERU that day or the session before.

  5. 22 May 2026+5.9%
  6. 14 May 2026-7.5%
  7. 5 Feb 2026-11.5%
  8. 16 Jan 2026+11.2%

    Nothing announced by VERU that day or the session before.

Share of unusual movement by asset

For each asset, the share of VERU's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
enobosarm
events and moves
1114%
Other company news (earnings, financing, releases naming no asset)—51%
Sessions with no dated event—35%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Androgen receptor (selective)Small molecule
Obesity

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
2026-09-30 Financial ReportEarnings report
Expected report date 2026-12-16 · Fiscal period ending 2026-09-30
What to watch
2027 (1)
October 2027 (1)
enobosarmPhase 2Obesity & Overweight, Mobility Disability, HOMA-IR
Est. primary completion 2027-10 · NCT07446998 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 January 2025Topline resultenobosarmPhase 2b QUALITY topline results
January 2025Topline resultenobosarmPhase 2b QUALITY topline: lean-mass primary endpoint met

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$4.3M$24M$7.0M-$5.5M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$3.1M$28M$2.7M-$8.9M operating cash flowreport ↗
2025-Q4—$1.3M$33M$5.3M-$6.2M operating cash flowreport ↗
2025-Q2$0$3.0M$15M$7.3M-$5.5M operating cash flowreport ↗
2025-Q1$0$3.9M$20M$7.9M-$7.7M operating cash flowreport ↗
2024-Q4—$5.7M$27M$8.9M-$11M operating cash flowreport ↗
2024-Q2$4.0M$4.9M$29M$11M-$5.7M operating cash flowreport ↗
2024-Q1$4.1M$3.0M—$10M-$5.7M operating cash flowreport ↗
2023-Q4$2.1M$1.6M—$8.3M-$6.0M operating cash flowreport ↗
2023-Q2$3.3M$2.9M——-$18M operating cash flowreport ↗
2023-Q1$6.6M$23M—$39M-$26M operating cash flowreport ↗
2022-Q4$2.5M$19M—$37M-$35M operating cash flowreport ↗
2022-Q2$9.6M$18M—$22M-$14M operating cash flowreport ↗
2022-Q1$13M$16M—$14M-$4.0M operating cash flowreport ↗
2021-Q4$14M$10M—$6.4M-$8.7M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$16M$16M$5.7M-$30M operating cash flowreport ↗

Veru did not disclose revenue for fiscal 2025, with prior-year revenue of $16.89M. R&D spend was $15.59M, up 21.7% YoY from $12.81M, while cash, cash equivalents and restricted cash were $15.79M at September 30, 2025, versus $24.9M at fiscal 2024 year-end. Net loss was $22.73M, narrowed from $37.8M in fiscal 2024.

The company highlighted positive Phase 2b QUALITY results for enobosarm in combination with a GLP-1 RA and said the FDA provided regulatory clarity that incremental weight loss is an acceptable approvable primary endpoint, with key secondary endpoints on physical function and body composition. Veru plans to initiate the Phase 2b PLATEAU study in calendar Q1 2026, with interim results anticipated in Q1 2027. After fiscal year end, the company completed a public offering for net proceeds of approximately $23.4 million.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$17M$13M$25M$9.4M-$22M operating cash flowreport ↗
2023-FY$16M$51M$9.6M$23M-$88M operating cash flowreport ↗
2022-FY$39M$71M—$21M-$48M operating cash flowreport ↗
2021-FY$61M$33M——-$16M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($5K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-13BARNETTE K GARY · Chief Scientific OfficerOpen-market purchase1,800$2.69$5KForm 4
2026-05-04FISCH HARRY · director, Chief Corporate OfficerAward / grant (derivative)160,000——Form 4
2026-05-04BARNETTE K GARY · Chief Scientific OfficerAward / grant (derivative)160,000——Form 4
2026-05-04Lu Lucy · directorAward / grant (derivative)104,000——Form 4
2026-05-04Rankowitz Michael L · directorAward / grant (derivative)100,000——Form 4
2026-05-04Hyun Grace · directorAward / grant (derivative)97,000——Form 4
2026-05-04Katzovitz Loren Mark · directorAward / grant (derivative)102,000——Form 4
2026-05-04Greco Michele · Chief Admin Officer and CFOAward / grant (derivative)164,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 56 reporting institutions held 3.4M shares ($7.1M, 20.1% of shares outstanding).

#InstitutionSharesValue
1Alyeska Investment Group, L.P.1,000,000$2.2M
2VANGUARD CAPITAL MANAGEMENT LLC539,382$1.2M
3OPPENHEIMER & CO INC196,300$434K
4GEODE CAPITAL MANAGEMENT, LLC184,622$408K
5Summit Financial, LLC151,783$335K
6MILLENNIUM MANAGEMENT LLC150,401$332K
7Ikarian Capital, LLC133,517$295K
8BlackRock, Inc.114,169$252K
9VANGUARD FIDUCIARY TRUST CO80,653$178K
10CHOREO, LLC75,263$166K
11RENAISSANCE TECHNOLOGIES LLC69,250$153K
12RAYMOND JAMES FINANCIAL INC67,561$149K
13STATE STREET CORP55,004$122K
14BLAIR WILLIAM & CO/IL48,000$106K
15CITADEL ADVISORS LLC44,482$98K